T he desire to have a good night's sleep is anyone's dream! When one must attend to a sick child with annoying upper respiratory tract infection (URTI) symptoms, such as cough, the temptation to use something to "give them comfort and rest " is tremendous. But do the claimed benefits of over-the-counter (OTC) preparations to "relieve" the cough and cold symptoms really bear out?
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The first use of nonprescription cough and cold preparations dates back to the early 1950s when antihistamines became available for purchase without prescription. In an unplanned clinical trial, 16 children <6 years of age received an antihistamine from their parents. 1 Compared with children whose parents did not use antihistamines, there was no significant difference in duration of cold or nasal symptoms. Since this time, a handful of randomized controlled trials evaluating the effects on children of OTC cough and cold remedies, such as antihistamines, antitussives, nasal decongestants, mucolytics, or some combination thereof, have been published. 2-6 The symptom most frequently evaluated in these studies has been frequency and severity of cough generally reported by parents using a cough scale. Drowsiness or sleepiness were reported as adverse effects, but not systematically evaluated as outcomes. Methodologic issues were present in these randomized controlled trials. Some of these studies were not blinded, whereas the randomization process or adequacy of patient population size was unclear in others. In none of these trials was the active compound(s) found to be better than placebo in relieving URTI symptoms.
In the July 2004 issue of Pediatrics, Paul et al. 7 described the results of a study comparing the effects of dextromethorphan (DM), diphenhydramine (DPH), and placebo on nocturnal cough and sleep quality for coughing children and their parents. The effects of these agents were evaluated in 100 patients during a single-dose, single-night study. The frequency and severity of cough and its impact on the quality of sleep of the child and parents were evaluated using a Likert scale. While the overall outcomes showed improvement for all 3 groups, when compared with placebo, DM and DPH were not better at improving nocturnal symptom relief for children with cough and sleep difficulty or improving the quality of sleep for their parents. The results of this study concur with findings from previous studies as far as the quality of cough, the major outcome studied in all other randomized controlled trials. 2- 6 The quality of sleep was not evaluated systematically as a primary outcome in some of the earlier trials. 2,4 Others reported descriptions such as "crankiness" and "excessive sleepiness" as adverse outcomes. 3 The scales used to evaluate sleepiness as an outcome in these studies are quite subjective and nonspecific and report on the duration rather than quality of sleep. 2-4 Paul et al. 7 evaluated the quality of sleep following DPH, which has sedative effects, as well as DM and placebo, which have no sedative effects. Sleep could be affected by a decreased number of coughing episodes as well as by the pharmacologic effect of the medications used to relieve URTI symptoms. It is not appropriate to compare the quality of sleep using agents that are primarily advocated as non-drowsy formulations (ie, DM) and those that have an inherent pharmacologic ability to cause drowsiness (ie, DPH). DM could improve the quality of sleep by reducing the episodes of cough at night, but such a correlation was not established in this study.
Antihistamines are usually marketed in combination with decongestants. They have no cough suppressant properties. Antitussive agents used as cough suppressants have no antihistamine properties. Codeine, which has coughsuppressant properties, is not available OTC. DM, categorized as a cough suppressant by the Food and Drug Administration (FDA), is available OTC as a pediatric liquid and lozenges. The mechanism of action of the antitussive and sedative effects of ethanolamine antihistamines have been studied in guinea pig models. 8 The ethanolamine antihistamines (ie, DPH, clemastine) showed minimal effects on capsaicin-induced cough, although sedation time was increased at the 30-mg and 100-mg/kg dose of DPH used in the study. The authors noted that the antitussive effects of ethanolamine antihistamines are independent of sedative effects and may require a different dosing regimen to elicit these effects.
As with many prescription medications, OTC products have also not been well studied in children. Proper dosage guidelines for use of OTC products in children are lacking. All 6 of the randomized controlled trials (5 in the English language) that have evaluated antihistamines, antitussives, decongestants, or combinations thereof have used manufacturer's recommended doses, which are, in general, extrapolations of adult doses. 2-6 If one was to truly determine the effectiveness of these agents on cough and cold symptoms, the trials would need to be designed appropriately to treat the symptoms under study using the most effective weight-based dosing regimen.
Several issues need attention here. What is the correct dose? Most cough and cold preparations are combinations of ≥2 active ingredients, and it is unclear as to which active ingredient the dose is based on or which has been used for determining maximum dose limits. These are tough questions to answer with fixed-combination products. As noted earlier, the drug dosing on the packages of these medications is based on extrapolation from adult dosing. There are no systematic pharmacokinetic evaluations of these agents. Thus, it is no surprise that, in many studies, these agents are reported as being no better than placebo. Are we giving enough drugs to elicit the right effect? As McLeod et al. 8 have pointed out, the doses of DPH required for antitussive effects may be different than those that induce sleep. The study by Paul et al. 7 is a single-dose study that used the manufacturer's currently recommended dose for DM. 7 Could the results have been different if the drugs were used several times during the study period? As the authors suggested, it is possible that the effect could have been different with DPH or DM if children were given either multiple doses throughout the day or repeated nocturnal doses. If the medications are dosed using sound guidelines, could they be better than placebo?
The use of OTC products in children is heavily influenced by advertising. Although there are no formal studies in children, the influence of direct-to-customer advertising on the use of prescription and nonprescription drugs in adults is well known; parents of children (as adults) would be no exception. 9,10 What is a pediatrician or pharmacist to do if a parent demands medications for symptom relief of cough and cold? While in some cases such prescriptions may be justified (especially if an allergic component is present that may respond to antihistamines), in other cases, such requests could be looked upon as an opportunity for parental education regarding the pros and cons of using such medications. If a parent requests the use of such OTC products at a pharmacy, the pharmacists have an opportunity to educate parents as well.
Among the systematic randomized controlled trials cited above, adverse effect data were reported in only 4 of the trials and commonly included symptoms such as drowsiness, diarrhea, and "hyperactive" behavior. 2-5 Some of the other more common adverse effects, such as anticholinergic effects of DPH that cause excessive drying of secretions resulting in mucus plugging, secondary infections, and possible delay in diagnosis of a more serious underlying problem, have not been studied. The literature contains many more reports of accidental overdose and adverse effects of OTC cough and cold preparations, some of them fatal. 11-13 In a case series of fatalities in infants, all of whom were <12 weeks old, DPH was used to induce sleep in at least 2 of the infants. While the doses given were not known, all infants had high DPH concentrations on postmortem examination. 11 In young infants, DPH can cause paradoxical central nervous system excitement, seizures, and death. 14 The precipitation of intracranial hemorrhages, some with fatalities, from OTC products containing the decongestant phenylpropanolamine led the FDA to issue a public warning and removal of these products from the market in the early 1990s. 15 The American Academy of Pediatrics (AAP) has provided guidelines for the safety of codeine and DM. 16 The AAP highlights the lack of efficacy data for codeine and DM as cough suppressants in children. For OTC use, DM is generally marketed in combination with decongestants and/or antihistamines. The efficacy of decongestants in children is not well understood. Both codeine and DM have addictive properties as well. Because efficacy data are lacking, suppression of cough may not be desirable in many conditions, such as bronchitis or asthma. Dosage guidelines for these agents are extrapolated from adults and are therefore imprecise in children; thus, the AAP does not encourage the use of these agents in children. It advocates better designed clinical trials and parental education regarding the lack of effectiveness of these agents as antitussive agents.
Most common cold symptoms are self-limited and tend to resolve within a few days without any treatment. There is no reliable evidence for or against the effectiveness of OTC products for relief of URTI symptoms in children, especially acute cough, the most common of these symptoms. The number of trials evaluating such effects is small and each has its limitations. Trials using combination products are difficult to conduct and interpret. The most commonly reported adverse effect in these trials is sleepiness or drowsiness. The dosage guidelines on the container or in the package insert can be confusing and subject to miswww.theannals.com V Bhatt-Mehta interpretation or misunderstanding by the parents. Since there are no definitive data on age-appropriate dosage guidelines or duration of use of OTC cough and cold products, use of these products in children should be avoided. Parents who insist on using such products must be counseled appropriately to ensure their understanding of appropriate use of such OTC products. Professional judgment must be used when providing such information. Maximum dose limitations per 24-hour period provided by the manufacturer vary depending on whether the product is a single compound or a combination product. Dose limits for each ingredient must be emphasized. The most common adverse effects of these products, drowsiness and sleepiness, must also be mentioned. The parents must be advised to seek further medical attention if cold and cough symptoms persist. Parental judgment in seeking such attention is prudent to avoid complications of what might appear to be simple cold symptoms.
As healthcare providers, we have the responsibility of educating parents about the appropriate use of OTC cough and cold preparations in children, especially the very young, and keeping the most vulnerable patient population safe and healthy. 
